| Cash Flow | 2025-06-30 |
|---|---|
| Share-based compensation | 325,217 |
| Net loss | -4,957,165 |
| Prepaid expenses and other current assets | -73,355 |
| Accounts payable and accrued liabilities | -1,117,921 |
| Accounts and other receivable | 18,159 |
| Gain on loan forgiveness | 0 |
| Depreciation and amortization | 93,405 |
| Net cash used in operating activities | -5,601,268 |
| Repayment of debt | 0 |
| Proceeds from issuance of series a-1 preferred shares and warrants | 1,540,820 |
| Proceeds from issuance of series b-1 preferred shares-Series B1Preferred Stock | 8,340,000 |
| Proceeds from issuance of common shares and warrants | 7,497,133 |
| Payments for issuance costs-Preferred Stock | 215,157 |
| Payments for issuance costs-Common Stock And Warrants | 294,935 |
| Payment for issuance costs of warrants | 23,446 |
| Net cash provided by financing activities | 16,844,415 |
| Effect of exchange rate changes on cash and cash equivalents | 81,223 |
| Net change in cash and cash equivalents | 11,324,370 |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)